PFE and JNJ Related Headlines
Go Back- Trump to announce prescription drug price agreements
- Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
